Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia
Abstract FMS-like tyrosine kinase 3- internal tandem duplication (FLT3-ITD) remains as one of the most frequently mutated genes in acute myeloid leukemia (AML), especially in those with normal cytogenetics. The FLT3-ITD and FLT3-TKD (tyrosine kinase domain) mutations are biomarkers for high risk AML...
Main Authors: | Juanjuan Zhao, Yongping Song, Delong Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-09-01
|
Series: | Biomarker Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40364-019-0170-2 |
Similar Items
-
Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
by: Motoki Eguchi, et al.
Published: (2020-07-01) -
The biology and targeting of FLT3 in pediatric leukemia
by: Colleen eAnnesley, et al.
Published: (2014-09-01) -
Clinical use of FLT3 inhibitors in acute myeloid leukemia
by: Sutamtewagul G, et al.
Published: (2018-10-01) -
Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
by: Musa Yilmaz, et al.
Published: (2020-10-01) -
FLT3 inhibitors in acute myeloid leukemia
by: Mei Wu, et al.
Published: (2018-12-01)